Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Single-cell spatial analysis in TNBC from NeoTRIPaPDL1

Giampaolo Bianchini • 8 Dec 2021
SABCS 2021
Breast Cancer Antibodies Atezolizumab Carboplatin Paclitaxel
NeoTRIPaPDL1

Giampaolo Bianchini, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses single-cell spatial analysis by imaging mass cytometry and immunotherapy response in patients with triple-negative breast cancer (TNBC) who were enrolled in the NeoTRIPaPDL1 trial (NCT02620280). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Giampaolo Bianchini

4:10
BioltaLEE: ctDNA dynamics in HR+/HER2- advanced breast cancer
Giampaolo Bianchini • 8 Dec 2021
2:31
COVID-19 related personalized risk-benefit ratio adaptation of breast cancer care
Giampaolo Bianchini • 15 Sep 2020
4:22
NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer
Giampaolo Bianchini • 15 Sep 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals